Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Illumina (ILMN) , which belongs to the Zacks Medical - Biomedical and Genetics industry.When looking at the last two reports, this genetic testing tools company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 115.52%, on average, in the last two quarters.For the last reported quarter, Illumina came out with e ...

Illumina, Inc. (ILMN) has announced a collaboration with NVIDIA (NVDA) to advance technology platforms for analyzing and interpreting multiomic data. By combining advancements in artificial intelligence (AI) with multiomic data at scale, the partnership seeks to optimize the analysis of vast amounts of data involved in multiomic research.The latest development aims to accelerate progress in clinical research, genomics AI development and drug discovery.ILMN Stock’s Trend in Response to the NewsFollowing the ...

公司概述 - Illumina 公司首席执行官 Jacob Thaysen 在 JPMorgan 医疗健康会议上发表演讲 介绍了公司的业务和未来机会 [3] - 公司将在演讲中涵盖四个主要领域 包括业务展望 2024 年第四季度和全年初步业绩 2025 年展望 新战略进展以及未来发展路径 [4] - Illumina 在过去超过 25 年的时间里 将新一代测序技术从新兴技术发展为生物学的基础工具 该技术已成为全球基因组研究和临床应用的重要组成部分 [5] 财务表现 - 公司将公布 2024 年第四季度和全年的初步业绩 并提供 2025 年的展望 [4] 战略发展 - Illumina 正在实施新战略 目标是从每千兆碱基成本转向以最低端到端成本获得最高质量洞察 [4] - 公司对新战略的进展感到满意 并对未来发展路径充满期待 [4]

关键要点总结 1 行业或公司 - 公司为Illumina Inc (NASDAQ:ILMN)，专注于下一代测序技术(NGS) [1] - 行业为生命科学工具与诊断领域 [1] 2 核心观点和论据 - Illumina在过去25年中推动了下一代测序技术(NGS)的发展，使其从新兴技术成为生物学的基础工具 [5] - NGS已在全球基因组研究和临床应用中占据重要地位 [5] - 2024年公司处于全球强势地位 [5] 3 其他重要内容 - 公司CEO Jacob Thaysen将在演讲中分享四个主要内容：业务展望、2024年Q4及全年初步业绩、2025年展望、新战略进展及未来路径 [3][4] - 演讲包含前瞻性声明和非GAAP指标，建议参考SEC文件 [3] - 会议时长为40分钟，前20分钟为演讲，后20分钟为问答环节 [1] 4 数据与百分比变化 - 无具体数据或百分比变化提及

收入表现 - 2024年第四季度收入约为11亿美元，同比增长1%[6] - 2024年全年收入约为43.3亿美元，同比下降2%（按固定汇率计算）[6] - 2024年按固定汇率计算的收入为43.25亿美元，同比下降2%[13] - 预计2025财年按固定汇率计算的收入增长为低个位数，收入范围约为42.8亿至44亿美元[6] 利润率 - 2024年第四季度GAAP运营利润率为16.7%，全年为34.2%[6] - 2024年第四季度非GAAP运营利润率为19.7%，全年为21.3%[6] - 预计2025财年非GAAP运营利润率约为23%[6] 每股收益 - 2024年第四季度GAAP稀释每股收益为0.77-0.79美元，全年为5.65-5.67美元[6] - 2024年第四季度非GAAP稀释每股收益为0.91-0.93美元，全年为4.12-4.14美元[6] - 预计2025财年非GAAP稀释每股收益增长约为10%[6] 现金流 - 2024年经营活动产生的现金流为12.1亿美元，自由现金流为10.7亿美元[6] - 2024年自由现金流为10.7亿美元，由经营活动产生的现金流12.07亿美元减去资本支出1.37亿美元计算得出[16]

SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2024 and preliminary outlook for fiscal year 2025 ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). The webcast can be accessed through Illumina's website at investor.illumina.com. Core Illumina Revenue of approxi ...

Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research, genomics AI development, and drug discovery. To optimize anal ...

Study will generate a key reference data set with Illumina Protein Prep solution SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep™, powered by SOMAmer® ...

SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2024 following the close of market on Thursday, February 6, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call D ...

Illumina, Inc. (ILMN) has announced a series of updates to its NovaSeq X Series. The company’s single-flow-cell NovaSeq X Sequencing System is now available for the first time, alongside the software v1.3 upgrade to elevate sequencing performance and advance data quality.In addition, the new NovaSeq X 25B 100 and 200-cycle kits are now available under Illumina's brand following the company's acquisition of Fluent.ILMN Stock’s Likely Trend Following the NewsAfter yesterday’s announcement, Illumina shares edg ...